Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00NAX
|
|||
| Former ID |
DAP000430
|
|||
| Drug Name |
Promazine
|
|||
| Synonyms |
Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychomotor agitation [ICD-11: MB23.M] | Approved | [1] | |
| Therapeutic Class |
Antipsychotic Agents
|
|||
| Company |
Wyeth Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20N2S
|
|||
| Canonical SMILES |
CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
|
|||
| InChI |
1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
|
|||
| InChIKey |
ZGUGWUXLJSTTMA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 58-40-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9583, 90371, 647046, 5236626, 7980397, 8153033, 10525853, 10528271, 11111651, 11111652, 11335594, 11360833, 11363760, 11366322, 11368884, 11372094, 11374833, 11377046, 11461805, 11466721, 11467841, 11484533, 11486502, 11488655, 11490833, 11492962, 11494680, 14848900, 29224004, 46504504, 47216716, 47216717, 47291075, 47365121, 47440189, 47515258, 47588936, 47959671, 47959672, 48416476, 49698885, 50006482, 50100325, 50104276, 50686916, 56352878, 57288820, 57322527, 85209395, 90341344
|
|||
| ChEBI ID |
CHEBI:8459
|
|||
| SuperDrug ATC ID |
N05AA03
|
|||
| SuperDrug CAS ID |
cas=000058402
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides caccae was decreased by Promazine hydrochloride (adjusted p-values: 4.88E-04). | |||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Promazine hydrochloride (adjusted p-values: 2.08E-04). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Promazine hydrochloride (adjusted p-values: 3.29E-03). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Promazine hydrochloride (adjusted p-values: 8.16E-06). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides thetaiotaomicron was decreased by Promazine hydrochloride (adjusted p-values: 8.35E-04). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Promazine hydrochloride (adjusted p-values: 9.92E-06). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Promazine hydrochloride (adjusted p-values: 4.33E-06). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Promazine hydrochloride (adjusted p-values: 6.81E-03). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Promazine hydrochloride (adjusted p-values: 1.13E-04). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Promazine hydrochloride (adjusted p-values: 1.67E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Akkermansia muciniphila was decreased by Promazine hydrochloride (adjusted p-values: 8.57E-05). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 3 | Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.